Jeong Hun Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeong Hun Oh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hee-Chul Shin
Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
1 shared publication - Heera Yoen
Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea
1 shared publication - Hong-Kyu Kim
Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea
1 shared publication - Hyun-Ah Kim
Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
1 shared publication - In-Chul Park
Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
1 shared publication Jiwon Park
Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea
1 shared publication
Latest Publications
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250439
Preoperative Breast MRI and Survival Outcomes in Women 50 Years or Younger with Breast Cancer
Undergoing preoperative MRI was associated with reduced risk of ipsilateral in-breast recurrence in patients 50 years or younger with breast cancer, with the greatest benefit observed in those with hormone receptor–negative cancers.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250439
Preoperative Breast MRI and Survival Outcomes in Women 50 Years or Younger with Breast Cancer
Undergoing preoperative MRI was associated with reduced risk of ipsilateral in-breast recurrence in patients 50 years or younger with breast cancer, with the greatest benefit observed in those with hormone receptor–negative cancers.
- Open Access
- 4 July 2023
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 105 (1) , 31-36
Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
Lee J, et al. Ann Surg Treat Res. 2023 Jul;105(1):31-36. https://doi.org/10.4174/astr.2023.105.1.31
- 4 July 2023
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 105 (1) , 31-36
Open AccessCan chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
Lee J, et al. Ann Surg Treat Res. 2023 Jul;105(1):31-36. https://doi.org/10.4174/astr.2023.105.1.31